The efficiency of a single product dedicated producing line is declining because of increasing yield of biopharmaceutical, diversity of products and etc. Also flexibility of facility, based on advance in production technology, standardization in manuf...
The efficiency of a single product dedicated producing line is declining because of increasing yield of biopharmaceutical, diversity of products and etc. Also flexibility of facility, based on advance in production technology, standardization in manufacturing process and quality risk control, enabled the management of multi-purpose facility such as CMO (Contract Manufacturing Organization) to increase worldwide. However, according to the characteristics of multi-purpose facility for multiple products, risk of cross-contamination between products is also increasing in a single facility. And mostly, the risk is increasing more on vaccines handling pathogenic/infectious substance. For this reason, condition for permission differs from each International Regulatory. Importance of validation on cleaning and inactivation is increasing in multi-purpose manufacturing facility whereas domestic biopharmaceutical CMO has a very small number of experiences and they are facing shortage of related data. In acordance with this assignment, through investigating 7 plants from 5 advanced biopharmaceutical manufacturing companies including advanced CMO, we compared the domestic and international criteria of area segregation, multi-purpose manufacturing facility, design and management method of proces equipment to prevent cross-contamination, to clasify the substance used for biopharmaceutical (e.g. vaccine) by risk and to investigate cleaning and inactivation method. Likewise, we recognized the assessment criteria and method by suggesting a way to derive maximum remaining permissible dose. Case study about design of live virus vaccine production facility, spore former vacine production facility and other microbial vaccine production facility, control of area, cleaning procedure of equipment and disinfecting of facility to prevent cros-contamination was conducted. And case study to obtain acceptance criteria of campaign change process and cleaning validation in microbial vaccine production facilty was investigated. This presents the specific protocol and SOP for designs, operations and controls of facility and equipment, cleaning and inactivation method, cleaningvalidation method to prevent the cross contamination in multiproduct facility (e.g. CMO and etc) so that will be a help to the domestic biopharmaceutical CMO.